BSX Analyst Ratings
Boston Scientific Corporation (BSX) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $62.37B, listed on NYSE, employing roughly 59,000 people, carrying a beta of 0.57 to the broader market. Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Led by Michael F. Mahoney, public since 1992-05-19.
Analyst Ratings
In the October 2026 monthly count, 32 analysts rated BSX: 8 Strong Buy, 18 Buy, 6 Hold, 0 Sell and 0 Strong Sell.
Twelve months earlier, in October 2025: 34 analysts, 7 Strong Buy, 25 Buy, 2 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $61.48
- Median Target
- $60.00
- High
- $100.00
- Low
- $48.00
- Targets Published, Last 12 Months
- 78
Recent Price Targets
The 5 most recent of 78 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 14, 2026 | Truist Financial | Not named | $51.00 | $42.85 |
| Oct 13, 2026 | Mizuho Securities | Not named | $55.00 | $43.84 |
| Oct 6, 2026 | Barclays | Not named | $48.00 | $42.19 |
| Oct 3, 2026 | Bernstein | Lee Hambright | $54.00 | $42.60 |
| Sep 23, 2026 | Wells Fargo | Larry Biegelsen | $48.00 | $44.62 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Citigroup | maintain | Neutral | Neutral |
| Sep 24, 2026 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Sep 21, 2026 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 17, 2026 | Citigroup | downgrade | Buy | Neutral |
| Sep 9, 2026 | BTIG | maintain | Buy | Buy |
Quantitative Rating
BSX carries a model grade of A- (overall score 4 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read BSX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked BSX analyst ratings questions
- What is the BSX consensus price target?
- As of the latest aggregator update, Boston Scientific Corporation (BSX) carries a consensus 12-month price target of $61.48. Target ranges run from a low of $48.00 to a high of $100.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on BSX?
- In the October 2026 monthly count, 32 analysts rated BSX, and the distribution tilts to the Buy side: 8 Strong Buy, 18 Buy, 6 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has BSX seen?
- The five most recent ratings actions on BSX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect BSX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.